

4. (Amended) The method of claim 3, wherein said attenuated measles virus is injected directly into said tumor.

5. (Amended) The method of claim 4, wherein said attenuated measles virus is provided in a formulation comprising an excipient.

6. (Amended) The method of claim 5, wherein said attenuated measles virus formulation is provided continuously to said mammal.

7. (Amended) The method of claim 5, wherein said attenuated measles virus formulation is provided in pulses to said mammal.

A² 9. (Amended) The method of claim 1, wherein said attenuated measles virus is administered systemically to said mammal.

11. (Amended) The method of claim 1, wherein said attenuated measles virus is administered at a dose greater than about 10^3 pfu.

12. (Amended) The method of claim 11, wherein said dose is about 10^5 pfus.

A³ 13. (Amended) The method of claim 11, wherein said dose is about 10^6 pfus.

14. (Amended) The method of claim 11, wherein said dose is about 10^7 pfus.

15. (Amended) The method of claim 11, wherein said dose is about 10^8 pfus.

16. (Amended) The method of claim 1, wherein said attenuated measles virus is provided in a composition further comprising attenuated mumps virus and attenuated rubella virus.

17. (Amended) The method of claim 1, wherein said attenuated measles virus is provided in a composition further comprising attenuated rubella virus.

18. (Amended) The method of claim 1, wherein said attenuated measles virus is genetically modified to express a marker polypeptide, and wherein expression of said marker polypeptide correlates with replication of said attenuated measles virus.

20. (Amended) The method of claim 1, wherein said cancer cells are selected from the group consisting of melanoma cells, carcinoma cells, glioma cells, and myeloma cells.

A4 21. (Amended) The method of claim 20, wherein said cancer cells are myeloma cells.

22. (Amended) The method of claim 21, wherein said myeloma cells are Non-Hodgkin's Lymphoma cells.

28. (Amended) The method of claim 1, wherein said attenuated virus is selected from the group consisting of the Edmonston Zagreb measles strain, the Edmonston-Enders strain, the Moraten strain, and the Moraten Berna strain.

AS 29. (Amended) The method of claim 1, wherein said attenuated virus comprises a strain obtained after serial passage of either the Moraten strain or the Moraten Berna strain on non-human cells.

30. (Amended) The method of claim 1, wherein said attenuated virus comprises a strain obtained after serial passage of the Edmonston strain, the Edmonston Zagreb strain, or the Edmonston Enders strain on non-human cells.

Please add claim 33 as follows:

A6 C-33. The method of claim 11, wherein said dose is about 10^{12} pfu []
